Larimar Therapeutics (LRMR) Return on Equity [ROE] (2014 - 2026)
Larimar Therapeutics' Return on Equity [ROE] came in at -170.99% for Q2 2026, down 88.80 percentage points from -82.19% a year earlier.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Return on Equity [ROE] (2014 - 2026) Analysis & Trends
For FY2025, Larimar Therapeutics' Return on Equity [ROE] was -138.05%, down 66.36 percentage points from FY2024.
- Return on Equity [ROE] has declined in each of the last three years, with a five-year change of -41.86 percentage points (FY2020 to FY2025).
- Going back by year, Return on Equity [ROE] was -71.70% in FY2024 (-28.34 pp), -43.36% in FY2023 (-1.69 pp), -41.67% in FY2022 (+23.83 pp) and -65.49% in FY2021 (+30.70 pp).
- The Q2 2026 figure represents the lowest quarterly Return on Equity [ROE] since Q1 2020.
- Year-over-year, Return on Equity [ROE] increased in 1 of the last seven quarters, with an average year-over-year change of -50.69 percentage points.
- The fastest year-over-year change in Return on Equity [ROE] over five years came in Q2 2023 (a gain of 45.86 percentage points), and the weakest in Q4 2025 (a drop of 109.79 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | - |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 84.40% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.97% |
| 10 | Larimar Therapeutics | 307.49 Mn | -299.58 Mn | - | -170.99% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -170.99% |
| Dec 31, 2025 | -158.89% |
| Sep 30, 2025 | -107.98% |
| Jun 30, 2025 | -82.19% |
| Mar 31, 2025 | -66.66% |
| Dec 31, 2024 | -49.10% |
| Sep 30, 2024 | -36.00% |
| Jun 30, 2024 | -29.77% |
| Mar 31, 2024 | -32.54% |
| Dec 31, 2023 | -47.88% |
| Sep 30, 2023 | -39.49% |
| Jun 30, 2023 | -35.13% |
| Mar 31, 2023 | -32.49% |
| Dec 31, 2022 | -31.82% |
| Sep 30, 2022 | -41.69% |
| Jun 30, 2022 | -80.98% |
| Mar 31, 2022 | -77.76% |
| Dec 31, 2021 | -73.95% |
| Sep 30, 2021 | -79.91% |
| Jun 30, 2021 | -67.50% |
API Access
Larimar Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=LRMR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "LRMR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=LRMR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();